Session Information
Date: Sunday, November 8, 2026
Title: (0440-0470) Rheumatoid Arthritis - Treatment Poster A
Session Type: Poster Session A
Session Time: 10:30AM-12:30PM
Background/Purpose: Rheumatoid arthritis (RA) is associated with a higher risk of venous thromboembolism (VTE) compared with the general population. The comparative risk of VTE among patients treated with methotrexate versus biologic DMARDs remains incompletely defined. We evaluated the incidence of VTE in RA patients initiating methotrexate compared with biologic DMARDs using a large multicenter database.
Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Rheumatoid arthritis (RA) is classified according to the 2010 ACR/EULAR classification criteria as the presence of clinical synovitis in at least one joint not better explained by another diagnosis, with a cumulative score ≥6/10 from 4 domains: joint involvement, serology, acute-phase reactants, and symptom duration. Adults ≥18 years with RA were identified in the TriNetX database. Patients were categorized into those who initiated methotrexate without prior bDMARD exposure (Cohort 1) or any bDMARD (Cohort 2) on or after January 1, 2015 through April 23, 2026. The index date was defined as the first qualifying prescription. The primary outcome was VTE (deep vein thrombosis or pulmonary embolism), assessed from 1 day post-index through available follow-up. 1:1 propensity score matching was performed on 29 characteristics including demographics (age, sex, race), comorbidities, and laboratory values. Kaplan-Meier survival analysis and Cox proportional hazards models compared VTE incidence between matched cohorts.
Results: Before matching, 115,879 methotrexate and 132,526 bDMARD patients were identified. After propensity score matching, 97,960 patients remained in each cohort. Baseline characteristics were well-balanced (standardized differences < 0.1 for all matched variables).
VTE occurred in 6,189 methotrexate-treated patients (6.3%) versus 6,407 bDMARD-treated patients (6.5%). Methotrexate was associated with a slightly lower risk of VTE (risk ratio 0.97, 95% CI 0.93-0.99) with an absolute risk difference of -0.2% (95% CI -0.4% to -0.0%, P=0.045).
In time-to-event analysis, bDMARD use was associated with a modestly increased hazard of VTE compared with methotrexate (HR 1.05, 95% CI 1.01-1.09; p< 0.01). Kaplan-Meier analysis showed a statistically significant difference between groups (log-rank χ²=6.95, p=0.008).
Conclusion: In this large propensity-matched analysis of RA patients, biologic DMARD therapy was associated with a small but statistically significant increase in VTE risk compared with methotrexate. Although the absolute difference was modest, these findings may suggest a potential association between immunosuppressive strategy and VTE risk, warranting further study.
Baseline Demographic Characteristics of Patients with Rheumatoid Arthritis Treated with Methotrexate (MTX) vs Biologic DMARDs, Before and After Propensity Score Matching
To cite this abstract in AMA style:
Khan M, Boice J, Gnegy K, Dolly A, Pokharel S, McMahon R, Shimpi A, Tran K, Khan M, Khan F, Rasul S, Iqbal A, Escuro E, Latos J. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate Versus Biologic DMARDs: A Real-World Analysis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-in-rheumatoid-arthritis-patients-treated-with-methotrexate-versus-biologic-dmards-a-real-world-analysis/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-in-rheumatoid-arthritis-patients-treated-with-methotrexate-versus-biologic-dmards-a-real-world-analysis/
